"Ọgwụgwọ ọrụ ebube maka ịbelata ibu" na-achọ ịbanye China!Novo Nordisk China na-akwado ụdị mbelata ibu nke Semaglutide n'afọ a

"Ọgwụgwọ ọrụ ebube maka ịbelata ibu" na-aga ịbanye China!Novo Nordisk China na-akwado ụdị mbelata ibu nke Semaglutide n'afọ a
March 8, ozi ọma na Novo Nordisk na-atụ anya arọ ọnwụ version nke Semaglutide Wegovy ga-mma na China afọ a, ngwaahịa ga-abụ mmalite nke onwe-ego ndị ọrịa, na e nwere oke na ọnụ ọgụgụ nke ndị ọrịa.N'akụkụ a, Novo Nordisk China kwadoro akụkọ a dị n'elu nye onye nta akụkọ na-agba ọsọ, "na-atụ anya ka a kwado ya n'afọ a, ozugbo enwere ike ịbara ndị ọrịa China buru ibu."

Wegovy bụ aha azụmaahịa bekee nke GLP-1 ọgwụ Semaglutide mepụtara Novo Nordisk maka ngosipụta mbelata ibu, nke akwadoro dị ka ọgwụ na-ebelata ibu na June 2021 na United States.Tesla CEO Musk kwuru otu oge na mgbasa ozi mgbasa ozi na ọ na-eji ọgwụ ahụ eme ihe maka oke ibu, a na-achọkwa ya otu oge dị ka "ọgwụ ọrụ ebube maka ibu ibu".

Na China, Semaglutide injection na ọgwụ ọnụ ka akwadoro maka ihe ngosi ọrịa shuga, nke a ga-anabata injection simethicone maka ire ahịa na China na Eprel 2021, wee banye na katalọgụ mkpuchi ahụike mba na 2022;A kwadoro Semaglutide ọnụ na Jenụwarị afọ a, wee bụrụ ọgwụ GLP-1 nke mbụ akwadoro maka ire ahịa na China.

Dịka onye nnọchi anya ọgwụ GLP-1, Semaglutide enweela ihe ịga nke ọma n'ahịa.Akụkọ gbasara ego Novo Nordisk nke 2023 gosiri na ire Wegovy rigoro 406% ruo ijeri $4.6, na-eduga usoro GLP-1 zuru ụwa ọnụ.Ọzọkwa n'ihi na nke a, ọtụtụ ụlọ ọgwụ ụlọ ọrụ okirikiri nhọrọ ukwuu nke Semaglutide biosimilar ọgwụ mmepe, ma ọtụtụ na-na mmalite ụlọ ọgwụ ogbo, dị ka Liju Group (000513), Han Yu Pharmaceutical (300199) na ọtụtụ ndị ọzọ ọgwụ ụlọ ọrụ na mbụ mara ọkwa na ụlọ ọrụ Semaglutide. akwadoro ogwu ogbugba iji mee nnwale ụlọ ọgwụ maka ihe ngosi metụtara njikwa ibu.

Ọ bụ uru na-ekwu na, yana Novo Nordisk a maara dị ka "GLP-1 duo" LLY na-akwalitekwa ndepụta nke GLP-1 arọ ọnwụ ọgwụ Tirzepatide na China, nke a na-atụkwa anya ka a kwadoro n'ụlọ.2023 August, LLY China kwuputara nke ahụ, dị ka webụsaịtị gọọmentị nke Centerlọ Ọrụ Nyocha Ọgwụ nke State Drug Administration si kwuo.Ngwa ndebanye aha maka ịgba ọgwụ Tirzepatide maka mmelite njikwa ibu ogologo oge na ndị ọrịa nwere oke ibu ma ọ bụ nwere opekata mpe otu nsogbu metụtara ibu na ndabere nke nri nwere obere kalori na mmega ahụ ka ukwuu anabatara nke ọma.

A kwadoro ihe ngosi ọrịa shuga maka Tirzepatide na US na Mee 2022, ọgwụ ahụ nyekwara $483 nde na ego ha nwetara na Lilly na 2022. A kwadoro ihe ngosi ọnwụ maka Tirzepatide na US maka ọnwụ arọ na Nọvemba 8, 2023, mgbe ihe na-erughị ala. ọnwa abụọ na-erughị $176 nde na ego ha nwetara.

Site na Novo Nordisk na LLY GLP-1 ọgwụ a na-atụ anya na a ga-akwado ya maka ihe ngosi ịbelata ibu na China, asọmpi dị n'etiti Novo Nordisk na LLY na egwu GLP-1 nwere ike ịmalite n'oge na-adịghị anya na China.